Intensified ovarian stimulation in a GnRH antagonist protocol with agonist triggering: A prospective, clinical feasibility study

Reproductive BioMedicine Online

Volumn 22, Issue 2, 2011, Pages 133-139

  Griesinger, Georg ^a   Berndt, Henriette ^a   Schultz, Laura ^a   Schultze Mosgau, Askan ^a   Diedrich, Klaus ^a   Von Otte, Sören ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

cryopreserved embryo transfer; GnRH agonist; GnRH antagonist; OHSS; ovarian stimulation; vitrification

Indexed keywords

FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; CRYOPRESERVATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HUMAN; LIVE BIRTH; OOCYTE MATURATION; OVARY HYPERSTIMULATION; QUESTIONNAIRE; VITRIFICATION;

ADULT; BIRTH RATE; COHORT STUDIES; CRYOPRESERVATION; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HORMONES; HUMANS; INCIDENCE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; TREATMENT OUTCOME;

EID: 79551546280     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rbmo.2010.10.017     Document Type: Article

References (23)

1. R. Babayof, E.J. Margalioth, and M. Huleihel Serum inhibin A, VEGF and TNF{alpha} levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial Hum. Reprod. 21 2006 1260 1265
2. M. Bals-Pratsch, S. Al-Hasani, and B. Schopper A simple, inexpensive and effective artificial cycle with exogenous transdermal oestradiol and vaginal progesterone for the transfer of cryopreserved pronucleated human oocytes in women with normal cycles Hum. Reprod. 14 1999 222 230
3. D. Bodri, J.J. Guillén, A. Galindo, D. Mataró, A. Pujol, and O. Coll Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study Fertil. Steril. 91 2009 365 371
4. P. Devroey, R. Boostanfar, N.P. Koper, B.M. Mannaerts, P.C. Ijzerman-Boon, B.C. Fauser ENGAGE Investigators A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol Hum. Reprod. 24 2009 3063 3072
5. L. Engmann, L. Siano, D. Schmidt, J. Nulsen, D. Maier, and C. Benadiva GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS Reprod. Biomed. Online 13 2006 639 644
6. L. Engmann, A. DiLuigi, D. Schmidt, J. Nulsen, D. Maier, and C. Benadiva The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study Fertil. Steril. 89 2008 84 91
7. B.C. Fauser, D. de Jong, and F. Olivennes Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization J. Clin. Endocrinol. Metab. 87 2002 709 715
8. R.E. Felberbaum, T. Reissmann, and W. Küpker Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility Eur. J. Obstet. Gynecol. Reprod. Biol. 61 1995 151 155
9. A. Golan, R. Ron-El, and A. Herman Ovarian hyperstimulation syndrome: an update review Obstet. Gynecol. Surv. 44 1989 430 440
10. G. Griesinger, K. Diedrich, B.C. Tarlatzis, and E.M. Kolibianakis GnRH antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis Reprod. Biomed. Online 13 2006 628 638
11. G. Griesinger, S. von Otte, and A. Schroer Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study Hum. Reprod. 22 2007 1348 1352
12. G. Griesinger, H. Berndt, L. Schultz, M. Depenbusch, and A. Schultze-Mosgau Cumulative live birth rates after GnRH agonist triggering of final oocyte maturation in patients at risk of OHSS: a prospective, clinical cohort study Eur. J. Obstet. Gynecol. Reprod. Biol. 149 2010 190 194
13. E.H. Hoomans, B.B. Mulder Asian Purgeon Study Group A group comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI J. Assist. Reprod. Genet. 19 2002 470 476
14. P. Humaidan, E.G. Papanikolaou, and B.C. Tarlatzis GnRHa to trigger final oocyte maturation: a time to reconsider Hum. Reprod. 24 2009 2389 2394
15. M. Kuwayama, G. Vajta, I. Shoko, and O. Kato Comparison of open and closed methods for vitrification of human embryos and the elimination of potential contamination Reprod. Biomed. Online 11 2005 608 614
16. M.A. Manzanares, J.L. Gómez-Palomares, E. Ricciarelli, and E.R. Hernández Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels Fertil. Steril. 93 2010 1215 1219
17. O. Nevo, T. Eldar-Geva, S. Kol, and J. Itskovitz-Eldor Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin Fertil. Steril. 79 2003 1123 1128
18. H.J. Out, S. Lindenberg, and A.L. Mikkelsen A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon®) in women undergoing ovarian stimulation Hum. Reprod. 14 1999 622 627
19. H.J. Out, I. David, and R. Ron-El A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles Hum. Reprod. 16 2001 1104 1149
20. E.G. Papanikolaou, C. Pozzobon, and E.M. Kolibianakis Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles Fertil. Steril. 85 2006 112 120
21. B. Popovic-Todorovic, A. Loft, H.E. Bredkjaeer, S. Bangsbøll, I.K. Nielsen, and A.N. Andersen A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment Hum. Reprod. 18 2003 2275 2282
22. L. Rombauts Is there a recommended maximum starting dose of FSH in IVF? J. Assist. Reprod. Genet. 24 2007 343 349
23. M.F. Verberg, N.S. Macklon, and G. Nargund Mild ovarian stimulation for IVF Hum. Reprod. Update 15 2009 13 29